Clinical Study: Analysis of Glycemic Control and Satisfaction with a Connected Smart Cap in Patients with Type 1 Diabetes Mellitus

Last updated: February 20, 2025
Sponsor: Fernando Sebastián Valles
Overall Status: Active - Not Recruiting

Phase

4

Condition

Diabetes Mellitus, Type 1

Diabetes Prevention

Diabetes And Hypertension

Treatment

CONNECTED SMART CAP

Clinical Study ID

NCT06845891
5350
5350
  • Ages > 18
  • All Genders

Study Summary

This clinical study evaluates the impact of the Cap INSULCLOCK device on glycemic control, treatment adherence, and patient satisfaction in adults with type 1 diabetes mellitus (T1DM). Despite advances in pharmacology and technology, a significant proportion of individuals with T1DM fail to achieve recommended glycemic targets, partly due to the complexity of insulin therapy and suboptimal adherence. Cap INSULCLOCK is a device that attaches to insulin pens, automatically recording injections and integrating data on glucose levels, insulin administration, food intake, and physical activity, with real-time Bluetooth transmission. Its use may enhance adherence and optimize metabolic control.

This study is a randomized, low-intervention clinical trial conducted at a single center, enrolling 42 patients, who will be randomized into two groups: one using the activated device and a control group using the device in a blinded mode. The primary objective is to assess differences in time above range (TAR >180 mg/dL) over the last 14 days of continuous glucose monitoring (CGM). Secondary objectives include evaluating HbA1c levels, time in range (TIR), frequency of hypoglycemic episodes, and patient satisfaction. Data will be analyzed using advanced statistical methods, and the intervention is expected to improve adherence, reduce glycemic variability, and enhance quality of life in individuals with T1DM

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and women aged 18 years or older.

  • Diagnosis of type 1 diabetes mellitus (T1DM).

  • Users of flash continuous glucose monitoring (FGM) sensors with >70% of recordeddata, including intake and insulin dose logs.

  • Adequate therapeutic adherence, with no missed appointments in the past year.

  • Time above range (TAR >180 mg/dL) >25%.

  • Ability to provide informed consent to participate in the study.

  • Access to technology for follow-up, including a smartphone with internetconnectivity and compatibility with the Insulcloud app.

Exclusion

Exclusion Criteria:

  • Current pregnancy.

  • Severe acute illness.

  • Exclusion criteria for the use of real-time continuous glucose monitoring (RT-CGM)systems as per the Framework Agreement of the Community of Madrid for RT-CGM use (SERMAS).

  • Inability to provide informed consent or to meet the study requirements for anyreason.

Study Design

Total Participants: 42
Treatment Group(s): 1
Primary Treatment: CONNECTED SMART CAP
Phase: 4
Study Start date:
February 28, 2025
Estimated Completion Date:
January 15, 2026

Connect with a study center

  • Hospital Universitario de La Princesa

    Madrid, 28006
    Spain

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.